Sobi Unveils Its Comprehensive Annual and Sustainability Report for 2025

Swedish Orphan Biovitrum AB, known as Sobi, has recently released its Annual and Sustainability Report for the year 2025. This document highlights the company's achievements in driving forward innovative therapies aimed at addressing the needs of individuals suffering from rare diseases.

At the heart of Sobi's mission lies a commitment to enhancing the lives of those affected by such conditions. The company has reported treating over 53,000 patients during 2025, utilizing its advanced medical solutions. This impressive figure underscores Sobi's dedication to making significant strides in healthcare accessibility and effectiveness, ensuring that eligible patients receive the necessary therapies.

From a financial perspective, Sobi experienced a notable increase in revenue for the year, which rose by 15% when adjusted for currency exchange rates, reaching SEK 28 billion. Such growth is a clear indication of the expanding recognition of Sobi's contributions to the biopharmaceutical industry, especially in the realm of rare diseases. The report also discusses advancements in Sobi's product pipeline, which has the potential to redefine treatment standards for various rare and severe ailments.

The Annual and Sustainability Report encompasses a detailed, audited review of the company's financial health, as well as a comprehensive Sustainability Statement. This aspect is particularly important, as it reflects Sobi's ongoing transition towards the Corporate Sustainability Reporting Directive (CSRD) in accordance with European standards. By aligning its activities with the new reporting requirements, Sobi aims to set a benchmark in transparency and responsibility.

In addition to its internal assessments, the report is integrated with Sobi's Task Force on Climate-related Financial Disclosures (TCFD) and adheres to the EU Taxonomy guidelines. Through these initiatives, Sobi showcases its dedication not only to health advancements but also to environmental sustainability and corporate responsibility.

The report is readily available on Sobi's official website, offering both the comprehensive Annual Report and the Sustainability insights to stakeholders and the public alike. The version published in the European Single Electronic Format (ESEF) ensures adherence to regulatory requirements, establishing clarity and accessibility for all parties.

For Sobi, the year 2025 represented not just a period of financial growth but also a time of strategic positioning as a leader in the biopharma sector dedicated to rare diseases. With approximately 1,900 employees scattered across regions including Europe, North America, the Middle East, Asia, and Australia, Sobi continues to foster a diverse workforce focused on innovative healthcare solutions.

In conclusion, Sobi's publication of its Annual and Sustainability Report for 2025 highlights both the advancements in treatment for rare diseases and the company's commitment to sustainable business practices. As Sobi forges ahead, it stands at the forefront of medical innovation, targeting the unmet needs of patients worldwide, while simultaneously placing a strong emphasis on environmental and social governance.